Urdu: ذیابیطس کی نئی جدید دوا | Sotagliflozin | Modern Medicine of DM | @Medurstand by Prof Aziz

Urdu: ذیابیطس کی نئی جدید دوا | Sota | Sotagliflozin | New Modern Medicine of DM | Medurstand by Prof Aziz ur Rehman Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor, offering a unique approach to blood sugar control. Unlike conventional SGLT2 inhibitors, it reduces glucose absorption from the intestine while also increasing glucose excretion through the kidneys. This dual action helps improve HbA1c, supports weight loss, and lowers blood pressure. It has also shown important benefits in reducing heart failure events and protecting kidney health in selected patients. But is it better than traditional SGLT2 inhibitors, and who should receive it? In this video, Prof. Aziz-ur-Rehman explains the science, clinical evidence, advantages, limitations, and practical role of sotagliflozin in modern diabetes care.